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The p53 gene plays an important role in cell cycle con-
trol, facilitating DNA repair activities in response to
DNA damage. Aberrant cell cycle control impairs
DNA repair and increases the probability of mutations
that can lead to carcinogenesis. The p53 gene is poly-
morphic at codon 72 (Arg/Pro) of its protein, which is
functionally distinct, leading to inquiry into its role in
carcinogenesis. In this hospital-based case-control study
of 289 newly diagnosed patients with melanoma and
308 cancer-free control subjects, we evaluated whether
the p53 codon 72 variant is associated with risk of cuta-
neous melanoma (CM). The controls were frequency-
matched to the cases by age, sex, and ethnicity.The fre-
quency of the p53 Arg allele was 78.2% in cases and
73.2% in controls (p¼ 0.045), and the genotype frequen-
cies of p53 Arg/Arg, Arg/Pro, and Pro/Pro were 62.6%,
31.1%, and 6.3%, respectively, in the cases, and 53.9%,
38.6%, and 7.5%, respectively, in the controls (p¼
0.096). Logistic regression analysis revealed that the p53
Arg/Arg genotype was associated with a signi¢cantly
increased risk of melanoma (adjusted odds ratio (OR)
¼ 1.43; 95% con¢dence interval (CI)¼ 1.02^2.02) com-
pared with other genotypes, and this association was
more evident in subgroups of older subjects (OR
¼ 2.32; 95% CI¼1.39^388), and subjects with Fitzpa-
trick’s skin type III or IV (OR¼1.69; 95% CI¼1.11^
2.59). In conclusion, this study found some evidence
that in subjects over 50, p53 Arg/Arg genotype is asso-
ciated with increased risk of CM as compared to geno-
types Arg/Pro or Pro/Pro. Further larger studies are
needed to substantiate our ¢ndings. Key words: Cell cycle/
genetic susceptibility/molecular epidemiology. J Invest Derma-
tol 121:1510 ^1514, 2003
C
utaneous melanoma (CM) is the most serious form
of skin cancer. In the United States, approximately
53,600 new melanoma cases and 7,400 related deaths
were predicted for the year 2002 (American Cancer
Society, 2002). In the past 30 years, the mortality
rate of melanoma has been climbing steadily from 2.0 per
100,000 in 1969 to 3.0 in 1999, and most of this increase was due
to increased mortality among men aged 65 years and older
(Weinstock, 2000; Geller et al, 2002). Epidemiological studies
have clearly demonstrated that genetic predisposition and sun ex-
posure play important roles in CM risk (Gilchrest et al, 1999;
Piepkorn, 2000; Goldstein and Tucker, 2001; Whiteman et al,
2001). Recent studies ( Jiang et al, 1999; Piepkorn et al, 2000; Bres-
sac et al, 2002) have provided some clues about the molecular
mechanisms underlying such genetic susceptibility. Several stu-
dies suggest that genetic events such as mutations in the p53 gene
may contribute to the etiology of melanoma (Zerp et al, 1999;
Goldstein et al, 2000; Goldstein and Tucker, 2001; Spatz et al,
2001), although other studies did not (Bastiaens et al, 2001).
The p53 tumor suppressor gene encodes a DNA-binding pro-
tein involved in both cell cycle arrest and apoptosis. In response
to DNA damage, the p53 protein accumulates in cells, translo-
cates to the nucleus, activates gene transcription, and ultimately
results in cell cycle arrest, which is thought to permit repair of
damaged DNA prior to cell division (Kaelin, 1999; Robles and
Harris, 2001). In addition, the p53 protein activates a pathway of
programmed cell death, presumably in cells with excessive DNA
damage (Robles and Harris, 2001). A large number of human tu-
mors, including CM, have mutations and deletions of the p53
gene that result in a loss of both tumor suppression function and
cell cycle control ( Jiang et al, 1999; Halachmi and Gilchrest, 2001).
It has been estimated that 21% of human melanomas harbor p53
mutations (Zerp et al, 1999). Mutations in the p53 gene frequently
lead to overexpression of p53 proteins, and abnormal p53 expres-
sion occurs in as many as 40% of primary melanomas (White-
man et al, 1998). Therefore, other genetic events may contribute
to abnormal p53 expression in addition to p53mutations. Because
p53 plays an important role in protecting against skin cancer in-
duced by ultraviolet (UV)-B radiation (Jiang et al, 1999; Cleaver
and Crowley, 2002) and UV-signature mutations in p53 are com-
mon in skin cancers (Kim et al, 2002), including melanoma due to
defective DNA repair (Spatz et al, 2001), alterations in the
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function of p53 may be important events in the development
of CM.
Early studies revealed the existence of two structurally di¡er-
ent p53 alleles resulting from the substitution of an arginine (Arg)
to a proline (Pro) at codon 72 (Matlashewski et al, 1987). These
two alleles are functionally distinct because of their di¡erent bio-
logical and biochemical activities (Thomas et al, 1999).The discov-
ery of this polymorphism has stimulated inquiry into the role of
this p53 variant in carcinogenesis (Marin et al, 2000). Molecular
epidemiological studies have investigated the association
between this p53 codon 72 polymorphism and the risk of cancer,
including cancer of the cervix (Helland et al, 1998; Josefsson et al,
1998; Andersson et al, 2001; Zehbe et al, 2001; Saranath
et al, 2002), lung (Wu et al, 2002; Fan et al, 2000), prostate (Henner
et al, 2001), bladder (Soulitzis et al, 2002), head and neck (Sourvi-
nos et al, 2001; Shen et al, 2002), and nonmelanoma skin
(Bastiaens et al, 2001; Marin et al, 2000). However, to date, none
of the p53 codon 72 genotypes has been conclusively linked to
risk of malignancy.
Because p53 plays an important role in skin carcinogenesis, we
hypothesized that the p53 Arg72Pro polymorphism is associated
with risk of melanoma. To test this hypothesis, we evaluated the
prevalence of this p53 polymorphism in a hospital-based case-
control study of 289 patients with incident CM and 308 cancer-
free control subjects frequency-matched to cases on age, sex, and
ethnicity.
MATERIALS AND METHODS
Study subjects The patients were those with newly diagnosed CM who
were referred to The University of Texas M. D. Anderson Cancer Center
between May 1994 and February 2001. There were no age or tumor stage
restrictions, but all CM cases were histopathologically reclassi¢ed
according to the newly revised American Joint Committee on Cancer
(AJCC) staging criteria (Balch et al, 2001a; Balch et al, 2001b). The cancer-
free control subjects were recruited from visitors to M. D. Anderson who
were genetically unrelated to the patients and were frequency-matched to
the cases by age (75 years), sex, and ethnicity. The purpose of frequency
matching was to permit our focus on the main e¡ect of the polymorphism.
Each eligible subject was interviewed to obtain data on age, sex, ethnicity
and other demographic and risk factors, including sun exposure history,
host characteristics (e.g., eye and hair color), and Fitzpatrick’s sun-reactive
skin type (Fitzpatrick, 1988).
After giving informed consent, each subject donated 30 ml of blood that
was collected in heparinized tubes. Because genotype frequencies often
vary among ethnic groups and few minority patients were recruited, only
non-Hispanic white subjects were included in this analysis. We excluded
those who previously had radiotherapy or chemotherapy, those who had
prior cancer or any recurrent malignancies. As a result, a total of 289
eligible melanoma patients and 308 frequency-matched control subjects
with complete questionnaires and p53 genotyping data were included in
this analysis. The research protocol was approved by the M. D. Anderson
Institutional Review Board.
Genotyping From each blood sample, a leukocyte cell pellet obtained
from the bu¡y coat by centrifugation of 1 ml of whole blood was used
for DNA extraction with the QIAGEN DNA Blood Mini Kit (QIAGEN
Inc., Valencia, CA) according to the manufacturer’s instructions. We used
a modi¢ed polymerase chain reaction (PCR) ^ restriction fragment
length polymorphism (RFLP) analysis, originally described by Kawajiri
et al (1993), to identify the p53 codon 72 polymorphism using the
primers 50 -ATCTACAGTCCCCCTTGCCG-30 and 50 -GCAACTGAC
CGTGCAAGTCA-30. We ampli¢ed the targeted fragment in a 25-mL
reaction mixture containing approximately 50 ng of genomic DNA
template, 12.5 pmol of each primer, 0.1 mM each dNTP, 1PCR bu¡er
(50 mM KCl, 10 mM Tris HCl, and 0.1% Triton X-100), 1.5 mM MgCl2,
and 1.0 units of Taq polymerase (Promega Corporation, Madison, WI).
The mixtures were subjected to PCRwith a MJ PTC-200 DNA Engine
(Peltier Thermal Cycler, MJ Research Inc., Watertown, MA). The PCR
pro¢le consisted of an initial melting step of 941C for 4 min; 35 cycles of
941C for 40 s, 561C for 30 s, and 721C for 30 s; and a ¢nal extension step of
721C for 10 min. The 296-bp fragment was then digested by BstU I (New
England BioLabs, Inc., Beverly, MA) overnight at 601C. The digested
product was separated on a 2.5% NuSieve 3:1 agarose gel (FMC
BioProducts, Rockland, ME) with ethidium bromide and photographed
with Polaroid ¢lm. The Arg allele has a BstU I restriction site, resulting in
two bands (169- and 127-bp), and the Pro allele lacks the BstU I restriction
site and therefore produces a single 296-bp band (Kawajiri et al, 1993). PCR
was conducted and the results were evaluated without any knowledge of
the subjects’ case-control status. Ninety (15%) of the samples were
randomly repeated using PCR single-strand conformational polymor-
phism (SSCP) analysis, and the results were 100% concordant.
Statistical analyses We ¢rst evaluated the di¡erences in the distributions
of demographic variables, sun exposure, select known host risk factors
(e.g., red hair, blue eyes, skin types), family history of cancer, and p53
genotype frequencies between cases and controls using the w2 test. The
association between p53 codon 72 polymorphism and melanoma was
estimated by computing the odds ratios (ORs) and their 95% con¢dence
intervals (CIs) from both univariate and multivariate logistic regression
analyses with the adjustment of age, sex and skin type. Dummy variables
were used in the logistic regression analysis to estimate the OR for
each category of exposure, with 1 being the Arg/Arg genotype and 0
being the other genotypes (Arg/Pro or Pro/Pro). Strati¢cation analyses
were performed to evaluate the modi¢cation e¡ect by the potential
confounding factors. All statistical analyses were performed with
Statistical Analysis System software (version 8; SAS Institute Inc., Cary,
NC).
RESULTS
This analysis included 289 melanoma patients and 308 cancer-free
control subjects. Of the 289 CM cases, 150 (51.9%) were classi¢ed
as stage I, 64 (22.1%) as stage II, 50 (17.3%) as stage III, 3 (1.0%) as
melanoma in situ, and 22 (7.6%) as unknown stage. However, the
allele and genotype frequencies of the p53 codon 72 polymorph-
ism did not di¡er statistically by these stages (data not shown).
Table I summarizes the selected characteristics of the subjects.
There were no signi¢cant di¡erences between cases and controls
in the distribution of age and sex, suggesting that the matching
on these two variables was adequate.The median age was 49 years
(mean, 49.2 years; range, 18^83 years) for the cases, and 50 years
(mean, 50.4 years; range 19^87 years) for the controls. There were
no statistically signi¢cant di¡erences in the distribution of educa-
tion, annual family income, or family history of cancer between
the cases and the controls (Table I). However, the frequencies of
the classical phenotypic traits (such as blue eyes, blonde or red
hair, skin type I^II and severe sunburn more than 5 times) were
signi¢cantly higher in CM patients than in control subjects, con-
¢rming that these risk factors are involved in the etiology of CM
in this study population.
The allele frequencies and genotype distribution of p53Arg72-
Pro polymorphism in cases and controls are summarized inTable
II. The distribution of the genotypes among the control subjects
was in agreement with the Hardy^Weinberg equilibrium
(p¼ 0.960). The Arg/Arg, Arg/Pro, and Pro/Pro genotype fre-
quencies were 62.6%, 31.1%, and 6.2%, respectively, in the cases,
and 53.9%, 38.6%, and 7.5%, respectively, in the controls
(p¼ 0.096). The p53 72Arg allele frequencies were 78.2% in the
cases and 73.2% in the controls (p¼ 0.045), suggesting that this
Arg allele may be a risk allele for CM. There was no signi¢cant
di¡erence in age of onset among CM patients grouped by the p53
genotype (data not shown).
Multivariate logistic regression analysis was used to evaluate
the association between the p53 genotype and the risk of CM
(Table II).When the homozygous Pro/Pro genotype was used as
the reference group, the Arg/Arg genotype was associated with a
nonsigni¢cantly increased risk (adjusted OR¼1.34, 95%
CI¼ 0.67^2.69), while the heterozygous Arg/Pro genotype was
not associated with the risk (adjusted OR¼ 0.92, 95%
CI¼ 0.45^1.90). Because the Pro/Pro genotype was relatively in-
frequent in both cases and controls and there was no risk asso-
ciated with the Arg/Pro heterozygotes compared with the Pro/
Pro homozygotes, we combined the Arg/Pro and Pro/Pro geno-
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types to form a reference group. When using this combined
reference group, the Arg/Arg genotype was signi¢cantly asso-
ciated with an increased risk of CM (adjusted OR¼1.43, 95%
CI¼1.02^2.02). These genotype groups (p53 codon 72 Arg/Arg
vs Arg/Pro and Pro/Pro) were further examined by strati¢cation
of select variables (Table III). The association between the Arg/
Arg genotype and the risk of CM was more pronounced in older
subjects (450 years; the median age of the controls), and the fre-
quency of the Arg/Arg genotype was signi¢cantly higher in CM
cases (65.6%) than in controls (46.7%) among these older subjects
(adjusted OR¼ 2.32, 95% CI¼1.39^3.88). Interestingly, this
association was also more pronounced among subjects with skin
type III or IV (adjusted OR¼1.69, 95% CI¼1.11^2.59) than
among those with skin type I or II (adjusted OR¼1.04, 95%
CI¼ 0.57^1.87).
DISCUSSION
In this hospital-based case-control study of CM, we demon-
strated an increased risk of CM associated with the p53 72Arg al-
lele, particularly in subgroups of individuals more than 50 years
of age, and subjects with skin type III or IV, suggesting that the
p53 72Arg allele represents a potential risk for CM.To our knowl-
Table I. Frequency distributions of selected variables and risk factors in melanoma patients and control subjects
Cases (n¼ 289) Controls (n¼ 308)
Variable No. % No. % P valuea
Age (years) 0.409
p50 158 54.7 158 51.3
450 131 45.3 150 48.7
Sex 0.950
Male 149 51.6 158 51.3
Female 140 48.4 150 48.7
Education (years)b 0.972
p12 97 33.9 94 34.1
412 189 66.1 182 65.9
Annual family incomeb 0.308
o$35,000 69 24.1 77 27.9
X$35,000 217 75.9 199 72.1
Family history of cancerb 0.931
yes 166 58.2 160 58.6
no 119 41.8 113 41.4
Eye colorb 0.002
Blue 112 39.0 77 27.0
Other than blue 175 61.0 208 73.0
Hair colorb o0.001
Blonde or red 109 38.9 58 20.7
Brown, black and others 171 61.1 222 79.3
Skin type (Fitzpatrick’s)b o0.001
i^ii (easily burn, no or light tan) 123 43.3 75 26.5
iii (moderate burn and tan) 98 34.5 73 25.8
iv (no burn, good tan) 63 22.2 135 47.7
Severe sunburn experiencesb o0.001
45 times 79 27.6 38 13.4
1^5 times 132 46.2 129 45.6
No 75 26.2 116 41.0
aTwo-sided w2 test.
bThe totals in these categories are not equal to the total number of the cases and controls because of missing data in these categories.
Table II. Frequency distribution of p53 codon 72 polymorphism between cases and controls and its association
with risk of melanoma
Cases (N¼ 289) Controls (N¼ 308)
p53 Codon 72 Genotype No. (%) No. (%) ORc (95% CI)
a ORa (95% CI)
a
Pro/Pro (ref.) 18 (6.3) 23 (7.5) 1.00 1.00
Arg/Pro 90 (31.1) 119 (38.6) 0.97 (0.49^1.90) 0.92 (0.45^1.90)
Arg/Argb 181 (62.6) 166 (53.9) 1.39 (0.73^2.67) 1.34 (0.67^2.69)
Arg allele frequency (%)c 78.2 73.2
Pro/Pro or Arg/Pro (ref)d 108 (37.4) 142 (46.1) 1.00 1.00
Arg/Arg 181 (62.6) 166 (53.9) 1.43 (1.03^1.99) 1.43 (1.02^2.02)
aObtained from logistic regression models; ORc: Crude OR; ORa: Adjusted ORwith adjustment for age and sex.
bTwo-sided chi-square test for genotype distributions between cases and controls, p¼ 0.096.
cTwo-sided chi-square test for allele frequencies between cases and controls, p¼ 0.045.
dTwo-sided chi-square test for combined genotype distributions between cases and controls, p¼ 0.031.
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edge, this is the ¢rst large molecular epidemiological study exam-
ining the association between p53 codon 72 polymorphism and
the risk of CM. Consistent with our hypothesis, these ¢ndings
suggest that this polymorphism may play a role in the etiology
of CM.
The p53 gene is a well-studied tumor suppressor gene that is
critical in cell cycle control, DNA repair, and apoptosis in re-
sponse to DNA damage. p53 codon 72 polymorphism in£uences
the ability of certain conformational p53 mutants to form stable
complexes with p73, a homolog of the tumor-suppressor protein
p53, which can activate p53-responsive promoters and induce
apoptosis in p53-de¢cient cells in vitro (Marin et al, 2000).
Furthermore, there is some evidence for the preferential mutation
and expression of the p53 72Arg allele in nonmelanoma skin can-
cer, and all p53 mutants bound to p73 in the skin-derived cell
lines contained the 72Arg allele (Marin et al, 2000). These func-
tional data suggest that p53 codon 72 a¡ects the biological beha-
vior of mutant p53 in skin cancer and are consistent with the
notion that the Pro/Pro genotype confers protection against
UV-induced cancers.
Several case-control studies had been conducted to investigate
the association between p53 codon 72 polymorphism and the risk
of nonmelanoma skin cancer. Recently, McGregor et al (2002)
found a signi¢cant association between p53 Arg homozygosity
and nonmelanoma skin cancer in a case-control study of 92 renal
transplant recipients with skin cancer and 156 skin type-matched
controls. In another case-control study of 157 control subjects and
87 patients with cutaneous squamous cell carcinoma, 114 with ba-
sal cell carcinoma and 120 with malignant melanoma, Bastiaens
et al (2001) found no association between this p53 polymorphism
and the risk of any type of skin cancer. Marshall et al (2000) stu-
died the p53 codon 72 genotype in long-term survivors of renal
transplantation and found no di¡erences in allele or genotype fre-
quency between 55 subjects who developed skin tumors after re-
nal transplantation and 167 subjects who did not. Similar results
were observed in another small hospital-based case-control study
of 55 patients with cutaneous squamous cell carcinoma and 115
matched volunteer control subjects (O’Connor et al, 2001). How-
ever, these studies su¡ered from possible problems in study
designs, such as small sample size, unsuitable controls, or the use
of tumor material in which loss of heterozygosity may have in-
£uenced the genotype outcome (Quinn et al, 1994).
In this study with a relatively large sample size and frequency-
matched design, we found that the p53 Arg/Arg genotype was
signi¢cantly associated with an increased risk of CM.The ¢nding
that elevated risk of CM in older (450 years) subjects with the
p53 Arg/Arg genotype is intriguing, because older people have
been reported to have higher lifetime cumulative UV exposure
than younger people (Fears et al, 2002).We observed a signi¢cant
di¡erence in the distribution of p53 Arg/Arg genotype between
younger and older subjects in the control group, probably because
this p53 polymorphism may be associated with sun exposure that
is associated with age, although we cannot exclude the possibility
that this di¡erence may be due to chance. The potential gene^
environment interaction is further suggested by a signi¢cantly
increased risk of CM associated with the p53 Arg/Arg genotype
among subjects with skin type III or IV. Our results showed that
the p53 72Arg allele was signi¢cantly more prevalent in subjects
with skin type I or II (fair skin susceptible to sunburn) than those
with skin type III or IV (moderate or dark skin not susceptible to
sunburn) among the control subjects, which is also consistent
with a recent ¢nding in nonmelanoma skin cancer (McGregor
et al, 2002), suggesting p53 codon 72 Arg/Arg homozygotes are
associated with skin type.
One possible bias in a hospital-based case-control study such as
ours is a selection bias in the genotype distribution of the control
group. However, in our control group, the frequencies of the p53
Arg/Arg genotype and Arg allele are consistent with those re-
ported for the control subjects in previous studies (Josefsson et al,
1998). Josefsson et al (1998) genotyped 626 population-based con-
trol subjects in Sweden and observed frequencies of 50.0% for the
Arg/Arg genotype and 69.0% for the Arg allele. Hildesheim et al
(1998) reported frequencies of 51.8% for the Arg/Arg genotype
and 71.8% for the Arg allele in 245 Caucasian subjects in the east-
ern United States. Similar frequencies were also observed in 225
Caucasian control subjects from Norway, with 54% for the Arg/
Arg genotype and 74.2% for the Arg allele (Helland et al, 1998).
These data suggest that our control subjects were not di¡erent
Table III. Strati¢cation analyses of p53 codon 72 genotype frequencies, ORs, and 95% CIs by selected patient characteristics
Cases (n¼ 289) Controls (n¼ 308) Adjusted OR (95% CI)a
Arg/Pro or Pro/Pro Arg/Arg Arg/Pro or Pro/Pro Arg/Arg Arg/Pro or Pro/Pro Arg/Arg
Total 108 (37.4) 181 (62.6) 142 (46.1) 166 (53.9) 1.0 1.43 (1.02^2.02)
Age (years)
p50 63 (39.9) 95 (60.1) 62 (39.2) 96 (60.8) 1.0 0.94 (0.59^1.50)
450 45 (34.4) 86 (65.6) 80 (53.3) 70 (46.7) 1.0 2.32 (1.39^3.88)
Sex
Male 52 (34.9) 97 (65.1) 73 (46.2) 85 (53.8) 1.0 1.53 (0.94^2.50)
Female 56 (40.0) 84 (60.0) 69 (46.0) 81 (54.0) 1.0 1.35 (0.84^2.18)
Family history of cancer
Yes 64 (38.6) 102 (61.4) 77 (48.1) 83 (51.9) 1.0 1.45 (0.93^2.28)
No 43 (36.1) 76 (63.9) 47 (41.6) 66 (58.4) 1.0 1.38 (0.79^2.40)
Severe sunburn experience
Yes 79 (37.4) 132 (62.6) 78 (46.7) 89 (53.3) 1.0 1.41 (0.92^2.14)
No 28 (37.3) 47 (62.7) 51 (44.0) 65 (56.0) 1.0 1.43 (0.77^2.64)
Skin type (Fitzpatrick’s)
I-II (easily burn, no or light tan) 49 (39.8) 74 (60.2) 31 (41.3) 44 (58.7) 1.0 1.04 (0.57^1.87)
III-IV (moderate or no burn, good tan) 56 (34.8) 105 (65.2) 99 (47.6) 109 (52.4) 1.0 1.69 (1.11^2.59)
Eye color
Blue 41 (36.6) 71 (63.4) 38 (49.4) 39 (50.6) 1.0 1.66 (0.92^3.00)
Other than blue 66 (37.7) 109 (62.3) 92 (44.2) 116 (55.8) 1.0 1.38 (0.90^2.11)
Hair color
Blonde or red 43 (39.4) 66 (60.6) 28 (48.3) 30 (51.7) 1.0 1.45 (0.75^2.82)
Brown, black and others 63 (36.8) 108 (63.2) 100 (45.0) 122 (55.0) 1.0 1.42 (0.94^2.15)
aAdjusted for age, sex and skin type within the strata accordingly.
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from the general Caucasian population in this genotype distribu-
tion and therefore were unlikely selected for this polymorphism.
Because the 95% CI of the odds ratio (main e¡ect) was border-
line, we cannot completely rule out the possibility that the di¡er-
ences may be confounded by other factors such as skin type.
However, with adjustment for skin type, the p53 Arg/Arg
homozygotes still had signi¢cantly increased risk of melanoma,
suggesting that the p53 codon 72 genotype may play an indepen-
dent role in risk of melanoma, even though this genotype is re-
lated to skin type.
In conclusion, this study found some evidence that in subjects
over 50, the p53 Arg/Arg genotype is associated with increased
risk of CM as compared to genotypes Arg/Pro or Pro/Pro, after
adjusting for sex and skin type. However, because this study is
relatively small, the ¢nding may have been due to chance.
Further larger studies simultaneously measuring p53 genotypes
or haplotypes as well as p53 mutations in the tumors, along with
other risk factors for CM, are needed to further con¢rm our
¢ndings.
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